ArticleNature communications2026
Spatial transcriptomic atlas of aggressive osteosarcomas reveals shared immune landscape and targetable surface markers.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Tumor-associated osteoclasts converge on a matrix-sulfation program across human bone tumors.Frontiers in cell and developmental biology · 2026Article
- Navigating the immunosuppressive abyss: current hurdles and innovative breakthroughs in neoadjuvant immunotherapy for osteosarcoma.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Osteosarcoma is characterized by extensive inter- and intra-tumoral heterogeneity, contributing to treatment resistance and poor outcomes. Here, we present a comprehensive spatial transcriptomics analysis of osteosarcoma, encompassing primary tumors and local or metastatic relapses across diverse phenotypic subtypes. Despite this heterogeneity, we identify a nine-gene cell surface signature with theranostic potential, validated in independent datasets and shown by immunohistochemistry to be distributed across distinct tumor compartments, supporting multi-targeted therapeutic strategies. Analysis of the tumor immune microenvironment reveals systematic lymphoid exclusion, differential myeloid infiltration patterns, and a type I interferon response signature that may explain the failure of IFN-α supplementation in prior trials. Notably, we provide evidence of monocyte-derived osteoclastic differentiation within human osteosarcoma lung metastases, identifying precursor populations with complex secretory phenotypes representing potential immunomodulatory targets. This study offers biological insights and translational opportunities while providing a resource for the osteosarcoma research community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.